

## References

I-136

1. Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: A novel therapeutic approach to primary effusion lymphoma. *Blood*. 2013; 122(7): 1233-1242.
2. Burris HA. Developments in the use of antibody-drug conjugates. *Am Soc Clin Oncol Educ Book*. 2013; 2013: 99-102.
3. Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naïve relapsed/refractory Hodgkin lymphoma. *Leukemia & Lymphoma*. 2013; 54(10): 2144–2148.
4. Garnock-Jones KP. Brentuximab vedotin: A review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. *Drugs*. 2013; 73: 371–381.
5. Han TH, Chen R, Advani R, et al. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. *Cancer Chemother Pharmacol*. 2013; 72: 241–249.
6. Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: An anti-CD30 antibody–drug conjugate. *Am J Health-Syst Pharm*. 2013; 70: 589-597.
7. Ogura M, Tobinai K, Hatake K, et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. *Cancer Sci*. 2014; 105: 840-846.
8. National Comprehensive Cancer Network (NCCN). Brentuximab vedotin. NCCN Drugs and Biologics Compendium®. 2018.
9. Chen R, Chen B. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. *Drug Design, Development And Therapy*. March 23, 2015;9:1729-1733.
10. Gravanis I, Tzogani K, Pignatti F, et al. The european medicines agency review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. *The Oncologist*. January 2016;21(1):102-109.
11. Gandolfi L, Pellegrini C, Zinzani P, et al. Long-term responders after brentuximab vedotin: single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients. *The Oncologist*. 2016;21(12):1436-1441.
12. Kuznar W. Brentuximab vedotin improves responses lasting 4 months in cutaneous T-cell lymphoma. *American Health & Drug Benefits*. 2017;10:14-16.
13. Rubio-Gonzalez B, Zain J, Garcia L, Rosen S, Querfeld C. Cutaneous gamma-delta T-cell lymphoma successfully treated with brentuximab vedotin. *JAMA Dermatology*. 2016.
14. Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. *Journal of Clinical Oncology*. 2015;33(32):3750-3761.

15. Jacobsen ED, Sharman JP, Oki Y, Advani RJ, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. *Blood*. 2015;125(9):1394-1402.
16. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, and Rakhshandra T. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphotoid papulosis. *Journal of Clinical Oncology*. 2015;33(32):3759-3768.
17. Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, et al. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review. *Crit Rev Oncol Hematol*. 2017;109:42-50.
18. Brentuximab vedotin. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
19. Adcetris® (Brentuximab vedotin) for injection [package insert]. Bothell, WA, Seattle Genetics, Inc. Revised 11/2017.
20. Brentuximab vedotin. Micromedex®Solutions Compendia. 2018.